You are here: Industry Insights > AstraZeneca

News List

AstraZeneca’s Vaccine, Dumped by the West, Helps Fill Gaping Need in Rest of World FirstWordPharma
December 27, 2021
AstraZeneca's COVID-19 vaccine Vaxzevria in not authorised in the US, and other countries such as Canada, Australia and those in Western Europe have shunned it after production problems
Vaxzevria significantly boosted antibody levels against Omicron WorldPharmaNews
December 24, 2021
AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study.(1)
Oxford and AstraZeneca aim to produce Omicron-targeted version of vaccine pharmatimes
December 22, 2021
Calls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates.
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study WorldPharmaNews
December 20, 2021
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralising activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
BenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio prnasia
December 17, 2021
BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF), discovered using BenevolentAI's platform, to its drug development portfolio.
Samsung Biologics and AstraZeneca expand manufacturing partnership to include COVID-19 and cancer therapies CPhIonline
December 16, 2021
CDMO currently manufacturing LAAB combination treatment and will start on cancer immunotherapy product from next year.
Samsung Biologics and AstraZeneca expand deal to include Covid-19 treatment Pharmaceutical-Technology
December 15, 2021
Samsung Biologics and AstraZeneca have expanded a strategic biopharmaceutical production partnership to include therapies for Covid-19 and cancer.
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy prnasia
December 14, 2021
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
US FDA grants EUA to AstraZeneca’s Evusheld in US for pre-exposure prophylaxis of COVID-19 expresspharma
December 10, 2021
Phase-III data showed at least six months of protection with one dose in high-risk participant population
FDA grants EUA to AstraZeneca’s antibody therapy for Covid-19 prevention Pharmaceutical-Technology
December 10, 2021
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for AstraZeneca’s antibody therapy Evusheld for the pre-exposure prophylaxis or to prevent Covid-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page